期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
黑色素瘤抑制蛋白有望成为转移性葡萄膜黑色素瘤的肿瘤血清学标记物
1
作者 Reiniger I.W. SchallerU.C. +1 位作者 haritoglouc. 陈立军 《世界核心医学期刊文摘(眼科学分册)》 2006年第5期38-39,共2页
PURPOSE: To assess the role of “melanoma inhibitory activity”(MIA) as a potential serum marker for screening and detection of metastatic uveal melanoma. Design: Prospective, clinical study. Material and methods: Ser... PURPOSE: To assess the role of “melanoma inhibitory activity”(MIA) as a potential serum marker for screening and detection of metastatic uveal melanoma. Design: Prospective, clinical study. Material and methods: Serum samples of 305 patients with uveal melanoma were collected. Serum samples were analysed by a one-step enzyme-linked immunosorbent assay (ELISA) to quantify the MIA serum levels. All patients underwent a standardized echography of the globe to evaluate maximum tumour height and were checked for systemic metastasis of the tumour by liver enzyme tests and ultrasonography of the liver. Results: Twenty patients (6.6%) had proven metastatic disease; eight of them developed it during follow-up. The mean serum concentration of MIA in the 285 patients withoutmetastasis was 6.72 ng/ml, whereas the mean serum concentration of MIA in the 20 patients with metastasis was 13.03 ng/ml (P< 0.001). The eight patients who developed metastatic disease during followup showed an MIA of 5.92 ng/ml before detection of metastasis and 12.21 ng/ml afterwards (P< 0.001). MIA serum levels did neither correlate with the tumour height or to whether local therapy had been applied. Conclusion: The elevation of MIA serumlevels in patients with metastatic disease from melanoma supports its promising role as a serum marker for monitoring patients with uveal melanoma. 展开更多
关键词 葡萄膜黑色素瘤 血清学标记物 肿瘤重量 抑制蛋白 转移性 酶联免疫吸附试验(ELISA) 前瞻性临床研究 血清浓度 随访期间 MIA
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部